REVOLUTION MEDICINES INC. news, videos and press releases
For more news please use our advanced search feature.
REVOLUTION MEDICINES INC. - More news...
REVOLUTION MEDICINES INC. - More news...
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
- Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Revolution Medicines Completes Acquisition of EQRx
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
- Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
- Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
- Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
- Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
- Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
- Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
- Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
- Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
- Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
- Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
- Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
- Revolution Medicines Announces Commencement of Public Offering of Common Stock